Diabetes: A duo helps better

Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone. Scientists from the Helmholtz Zentrum München, partner in the German Center for Diabetes Research, report in the journal Diabetes that this is due to a synergetic mechanism.

Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012. Scientists headed by Dr. Susanne Neschen and Prof. Dr. Martin Hrabě de Angelis from the Helmholtz Zentrum München, in cooperation with Ludwig-Maximilians-Universität München and drug manufacturer Sanofi Aventis, have discovered how the two substances reinforce each other.

Medicinal chain reaction

SGLT2 inhibitors promote the elimination of sugar in the urine and consequently reduce the blood sugar. However, paradoxically the body reacts to this with increased sugar production in the liver. And this is where metformin comes in: it slows down the body's own . The interaction of the two substances causes a drop in blood sugar levels that is effective and prolonged, and the reduction is greater than with either substance administered on its own.

"Combination effective with minimal side effects"

"The combination of drugs effectively reduces the blood sugar, and particularly also the blood sugar peaks after meals. In diabetic mice, the double therapy produced an improvement in the long-term level HbA1c within only two weeks," reports first author Neschen. "The duo consequently constitutes an effective treatment strategy for type 2 diabetes while also producing minimal side effects," adds Hrabě de Angelis.

Type 2 is a metabolic disorder that affects around 6 million people in Germany, and that number is steadily increasing. The Helmholtz Zentrum München focuses on developing new approaches for the prevention, diagnosis and treatment of major widespread diseases.

More information: Neschen, S. et al (2014). Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 (SGLT2) inhibitor by suppressing endogenous glucose production in diabetic mice, Diabetes, DOI: 10.2337/db14-0393

Related Stories

Study reverses current thought on treatment of cirrhosis

date Jun 19, 2014

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved ...

Recommended for you

Faster heart rate linked to diabetes risk

date May 22, 2015

An association between resting heart rate and diabetes suggests that heart rate measures could identify individuals with a higher future risk of diabetes, according to an international team of researchers.

EBV co-infection may boost malaria mortality in childhood

date May 21, 2015

Many people who live in sub-Saharan Africa develop a natural immunity to malaria, through repeated exposure to Plasmodium parasites. Even so, the disease kills close to half a million children per year, according ...

Three important things you didn't know about diabetes

date May 21, 2015

When we think of diabetes, we tend to think of rich people with poor lifestyles. A chronic disease linked with obesity, heart disease and worse outcomes for some infectious diseases, diabetes tends to be ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.